uniQure Begins First AAV Gene Therapy Trial for Huntington’s Disease

uniQure Begins First AAV Gene Therapy Trial for Huntington’s Disease

Publication date: Aug 05, 2020

Concepts Keywords
AMT MRI
Anesthesia Putamen
Atrophy Huntington’s disease
Biomarkers Biomarkers
Blood Brain Barrier RTT
Bone Biotechnology
Brain Clinical medicine
Burr Hole Branches of biology
Catheter Catheter
CEO Rare diseases
Clinical Trial Natural history disease
Cognitive Treatments Huntingtons disease
Cohort Eligible cross treatment
Cortex
Cross
EMA
Europe
Exon
Fast Track Designation
FDA
Gene
Genetic Mutation
Hemophilia
Huntingtin
Huntington
Liver
Matrix
Motor Skills
MRI
Muscle
Mutant
Natural History
Neurocognitive
Neuron
Neurons
Orphan Drug
Progressive
Protein
Putamen
Scalp
Spinal Fluid
Striatum
Tolerability
Viral Vector
Virus

Semantics

Type Source Name
disease MESH hemophilia
disease MESH atrophy
disease MESH rare diseases
disease MESH cognitive decline
disease MESH abnormalities
disease MESH hereditary disease
drug DRUGBANK Alpha-methyltryptamine

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *